These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32612954)

  • 1. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
    Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
    Front Oncol; 2020; 10():950. PubMed ID: 32612954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
    Zilenaite-Petrulaitiene D; Rasmusson A; Besusparis J; Valkiuniene RB; Augulis R; Laurinaviciene A; Plancoulaine B; Petkevicius L; Laurinavicius A
    Virchows Arch; 2024 Jan; ():. PubMed ID: 38217716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
    Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
    Front Oncol; 2021; 11():774088. PubMed ID: 34858854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
    Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
    Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
    Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
    Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
    Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
    Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity.
    Clark BZ; Onisko A; Assylbekova B; Li X; Bhargava R; Dabbs DJ
    Mod Pathol; 2019 Mar; 32(3):354-366. PubMed ID: 30327501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of progesterone receptor expression in a population-based analysis.
    Caldarella A; Barchielli A
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
    Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
    Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status.
    Wu H; Wang H; Guan S; Zhang J; Chen Q; Wang X; Ma K; Zhao P; Zhao H; Yao W; Jin F; Xiao Q; Wei M
    Oncotarget; 2017 Oct; 8(49):84996-85013. PubMed ID: 29156699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study.
    Nassar A; Radhakrishnan A; Cabrero IA; Cotsonis GA; Cohen C
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):433-41. PubMed ID: 20485156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.